<DOC>
	<DOC>NCT01663363</DOC>
	<brief_summary>The purpose of this clinical trial is to demonstrate that wavefront-guided LASIK is safe and effective for the correction of myopic refractive errors.</brief_summary>
	<brief_title>Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors</brief_title>
	<detailed_description />
	<mesh_term>Refractive Errors</mesh_term>
	<criteria>18 years of age or greater Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better Uncorrected visual acuity (UCVA) of 20/40 or worse Less than 0.75D difference between cycloplegic and manifest refraction sphere. Demonstration of refractive stability Anticipated postoperative stromal bed thickness of at least 250 microns Willing and capable of returning for followup examinations for the duration of the study. Women who are pregnant, breastfeeding, or intend to become pregnant over the course of the study Concurrent use of topical or systemic medications that may impair healing History of any medical conditions that could affect wound healing History of prior intraocular or corneal surgery, active ophthalmic disease, or other ocular abnormality Evidence of keratoconus, corneal irregularity, or abnormal topography in the operative eye(s) Known sensitivity or inappropriate responsiveness to any of the medications used in the postoperative course</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>refractive</keyword>
	<keyword>LASIK</keyword>
</DOC>